tldrdailynews.com logo

Eli Lilly's Promising Data and Guidance Set the Stage for Growth in 2023.

1 min read
Source: CNBC
Eli Lilly's Promising Data and Guidance Set the Stage for Growth in 2023.
Photo: CNBC
TL;DR Summary

Eli Lilly raised its outlook for the full year and reported positive obesity-trial data for potential blockbuster drug Mounjaro, making up for a first-quarter earnings miss. The news pushed shares up more than 2% in midday trading on Thursday.

Topics:business#business#earnings#eli-lilly#mounjaro#obesity-trial-data#outlook
Share this article
  1. Eli Lilly's higher guidance, Mounjaro data set the Club name up for a solid 2023  CNBC
  2. Eli Lilly Stock Jumps After Unveiling New Obesity Data As Mounjaro Shines | Investor's Business Daily  Investor's Business Daily
  3. Eli Lilly CEO David Ricks on Q1 earnings: This will be a year of both growth and investment  CNBC Television
  4. Eli Lilly misses on earnings but raises full-year guidance  CNBC
  5. Will Eli Lilly's Rally Continue? Here's How to Trade the Stock  RealMoney

Reading Insights

Total Reads

0

Unique Readers

10

Time Saved

0 min

vs 1 min read

Condensed

71%

135 → 39 words

Want the full story? Read the original article

Read on CNBC